Clinical trial
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03B in Second-Line Metastatic Participants
NCT04626518 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03B in Second-Line Metastatic Participants
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- December 17, 2020
- Completion date
- July 23, 2026
- Enrollment
- 263 (actual)
- Sites
- 51
Conditions
As the registry lists them; a condition with its own page is linked.